Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Reports Second Quarter 2017 Financial Results
SAN DIEGO , Aug. 3, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the second quarter 2017. "The second half of 2017 remains on track to be a significant time for all of Mirati's programs," said Charles
View HTML
Toggle Summary Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York
SAN DIEGO, July 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, announced today that they will host a Key Opinion Leader breakfast on the topic of Immuno-Oncology combinations on Tuesday, July 11 at 8:00am
View HTML
Toggle Summary Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors View HTML
Toggle Summary Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Reports First Quarter 2017 Financial Results View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
Following successful public offering, Company well positioned to deliver key data points for glesatinib, sitravatinib and immuno-oncology combinations in 2017
View HTML
Toggle Summary Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering of Common Stock View HTML